College of Pharmacy, Nankai University, Tianjin, People's Republic of China.
BMC Complement Altern Med. 2013 Aug 6;13:206. doi: 10.1186/1472-6882-13-206.
Qingfei Xiaoyan Wan (QFXY), a traditional Chinese formula, is widely used for relieving cough, asthma, upper respiratory tract infection, bronchitis, pneumonia, and etc. in clinic. Comparing with other anti-asthma drugs, it is characterised with moderate and persistent efficacy as well as few side effects, however, the underlying action mechanism still remains elusive. This study aimed to identify QFXY multi-target network regulation as an asthma controller.
This study established asthma model induced by histamine phosphate and acetylcholine chloride (His&Ach) in guinea pigs, which then were administered orally with QFXY. Hematoxylin-Eosin staining sections were applied for evaluating QFXY effect. In both Model and QFXY groups, customized microarrays and 2D electrophoresis were adopted to detect differentially expressed genes (diff genes) and proteins (diff proteins) respectively, and some diff proteins were identified with MALDI-TOF/MS. The checked diff genes and proteins underwent Cluster, GO and KEGG analysis. Based on GAD and HPRD databases, QFXY-asthma target regulation network was constructed.
His&Ach-induced asthma model of guinea pigs was established. HE sections presented anti-inflammation and anti-remodelling effects of QFXY. Comparing with the Model group, 55 diff genes and 6 diff proteins were identified in QFXY group. Validation by qPCR and Western blot showed the microarray and 2D data reliable. Furthermore, QFXY-asthma target regulation network was achieved.
A primarily combined genomic and proteomic screening of QFXY targets displayed a series of candidate genes and proteins, which indicated that the effect of QFXY relied on the combined mechanism, anti-inflammation and anti-remodelling, as well as influencing signal transduction in vivo.
清肺消炎丸（QFXY）是一种传统的中药配方，广泛用于临床缓解咳嗽、哮喘、上呼吸道感染、支气管炎、肺炎等。与其他抗哮喘药物相比，它具有中度和持续的疗效以及较少的副作用，但潜在的作用机制仍不清楚。本研究旨在确定 QFXY 作为哮喘治疗药物的多靶点网络调节作用。
本研究建立了由磷酸组织胺和氯化乙酰胆碱（His&Ach）诱导的豚鼠哮喘模型，然后用 QFXY 进行口服给药。采用苏木精-伊红染色切片评估 QFXY 的作用。在模型组和 QFXY 组中，分别采用定制的微阵列和二维电泳技术检测差异表达基因（diff genes）和蛋白质（diff proteins），并采用 MALDI-TOF/MS 鉴定部分 diff 蛋白质。对检查过的 diff 基因和蛋白质进行 Cluster、GO 和 KEGG 分析。基于 GAD 和 HPRD 数据库，构建了 QFXY-哮喘靶标调节网络。
建立了由 His&Ach 诱导的豚鼠哮喘模型。HE 切片显示 QFXY 具有抗炎和抗重塑作用。与模型组相比，QFXY 组中鉴定出 55 个差异表达基因和 6 个差异表达蛋白。qPCR 和 Western blot 的验证表明微阵列和 2D 数据可靠。此外，还构建了 QFXY-哮喘靶标调节网络。
QFXY 靶标进行的基因组和蛋白质组初步联合筛选显示了一系列候选基因和蛋白质，这表明 QFXY 的作用依赖于体内的联合机制，抗炎和抗重塑，以及影响信号转导。
